Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Gabelli & Company Highlights 6 Potential Gilead Sciences (GILD) Takeover Targets
November 18, 2016 11:27 AM ESTFollowing Gilead Sciences' (NASDAQ: GILD) setback with its JAK 1/2 inhibitor momelotinib in myelofibrosis, Gabelli & Company analyst Jing He said she anticipates the company could be interested in buying someone else in oncology or rare disease.
In oncology, the analyst highlighted:
Incyte (NASDAQ:... MoreIncyte (INCY) Seen Back of Gilead's (GILD) Takeover Target List Following Disappointing Momelotinib Data - Leerink
November 17, 2016 8:24 AM ESTLeerink Partners analyst Geoffrey Porges says Incyte (NASDAQ: INCY) is back on the list of Gilead Sciences' (NASDAQ: GILD) takeover targets after Gilead's disappointing phase III data for their JAK 1/2 inhibitor momelotinib in myelofibrosis.
"One consequence of this disappointment, however, is that it does restore INCY to the list of... More
Incyte (INCY) PT Lifted to $126 at BMO Capital Following Competitor Set-Back
November 17, 2016 6:42 AM ESTBMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $126.00 (from $121.00) as mixed data from Gilead's Phase 3 trials of momelotinib in myelofibrosis remove the only source of meaningful competition in the forseeable... More